Pentoxifylline

Generic Name: Pentoxifylline

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈N_₄O_₃

CAS Number: 6493-05-6

Unique Ingredient Identifier: SD6QCT3TSU

Background: Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties. Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated...

Indication: Pentoxifylline is indicated for the treatment of intermittent claudication in patients with chronic occlusive arterial disease. Pentoxifylline may improve limb function and reduce symptoms but cannot replace other therapies such as surgical bypass or removal of vascular obstructions.

Associated Conditions: Intermittent Claudication, Venous Leg Ulcer (VLU), Severe alcoholic liver disease

Associated Therapies: -

Clinical Trials

Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.

Phase 1

Not yet recruiting

Conditions: Alopecia Areata

Interventions: Drug: Betamethasone Valerate 0.1% Cream
Drug: Pentoxifylline
Drug: Metformin

First Posted Date: 2023-10-18

Last Posted Date: 2023-10-18

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT06087796

Locations: 🇪🇬
Assiut university, Assiut, Egypt

The Efficacy of Using Pentoxifylline in Patients Undergoing Breast Cancer Surgery

Phase 2

Recruiting

Conditions: Post-Surgical Complication
Breast Cancer Surgery

Interventions: Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2023-10-17

Last Posted Date: 2023-12-08

Lead Sponsor: Mansoura University

Target Recruit Count: 80

Registration Number: NCT06087237

Locations: 🇪🇬
Oncology center of Mansoura University, Mansoura, Egypt

Pentoxifylline Plus Carvedilol vs Carvedilol Monotherapy in Preventing New Decompensation in Stable Cirrhotic Patients With Prior Decompensation

Not Applicable

Not yet recruiting

Conditions: Liver Cirrhosis

Interventions: Drug: Carvedilol
Drug: Pentoxifylline

First Posted Date: 2023-09-18

Last Posted Date: 2023-10-03

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 180

Registration Number: NCT06041932

Locations: 🇮🇳
Institute of Liver & Biliary Sciences., New Delhi, Delhi, India

Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes

Phase 2

Not yet recruiting

Conditions: IVF

Interventions: Drug: pentoxifylline
Drug: tadalafil
Drug: Sildenafil

First Posted Date: 2023-08-02

Last Posted Date: 2023-08-03

Lead Sponsor: Beni-Suef University

Target Recruit Count: 200

Registration Number: NCT05971667

Locations: 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Beni Suef, Egypt

Combination Therapy Between Doxycycline, Pentoxifylline, and Nitazoxanide in Sexually Active Men

Phase 2

Not yet recruiting

Conditions: Sexually Transmitted Diseases

Interventions: Drug: Doxycyclin
Drug: Pentoxifylline
Drug: Nitazoxanide 500Mg Oral Tablet

First Posted Date: 2023-06-09

Last Posted Date: 2023-06-12

Lead Sponsor: Tanta University

Target Recruit Count: 100

Registration Number: NCT05897034

Effect of Pentoxifylline on Anemia in Hemodialysis Patients

Not Applicable

Not yet recruiting

Conditions: Hemodialysis Complication

Interventions: Drug: pentoxifylline

First Posted Date: 2023-02-01

Last Posted Date: 2023-02-06

Lead Sponsor: Alexandria University

Target Recruit Count: 80

Registration Number: NCT05708248

Locations: 🇪🇬
Mansoura University Hospital, Mansoura, Egypt

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol

Active, not recruiting

Conditions: Peripheral Artery Disease

Interventions: Drug: Cilostazol
Drug: Pentoxifylline

First Posted Date: 2022-12-02

Last Posted Date: 2023-07-19

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 10398

Registration Number: NCT05635370

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome

Not Applicable

Recruiting

Conditions: Eisenmenger Syndrome

Interventions: Drug: Pentoxifylline

First Posted Date: 2022-11-10

Last Posted Date: 2023-12-15

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 48

Registration Number: NCT05611268

Locations: 🇧🇷
Antonio Augusto Barbosa Lopes, São Paulo, Brazil

Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer

Early Phase 1

Conditions: Colo-rectal Cancer
Mucositis
Neuropathy;Peripheral

Interventions: Drug: Placebo
Drug: Pentoxifylline
Drug: FOLFOX-6 regimen

First Posted Date: 2022-10-21

Last Posted Date: 2022-10-21

Lead Sponsor: Tanta University

Target Recruit Count: 48

Registration Number: NCT05590117

Locations: 🇪🇬
Tanta University, Tanta, Gharbyia, Egypt

RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

Phase 2

Recruiting

Conditions: Post Acute Sequelae of COVID-19
Post COVID Condition
Long COVID

Interventions: Other: Placebo
Drug: Ibudilast
Drug: Pentoxifylline

First Posted Date: 2022-08-24

Last Posted Date: 2024-12-06

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 1000

Registration Number: NCT05513560

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
University Health Network, Osteoporosis Department, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy